We are live on ! Find out more
PVAM

Pacific View Asset Management Portfolio holdings

AUM $20.8M
1-Year Est. Return 20.08%
This Fund
S&P 500
This Quarter Est. Return
+5.69%
1 Year Est. Return
+20.08%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$126M
AUM Growth
-$6.42M
Cap. Flow
-$10M
Cap. Flow %
-7.91%
Top 10 Hldgs %
43.52%
Holding
126
New
18
Increased
44
Reduced
31
Closed
31

Top Buys

Rank Stock Value
1
GVA icon
Granite Construction
GVA
+$4.51M
2
ARRY
Array Biopharma Inc
ARRY
+$3.59M
3
AIMT
Aimmune Therapeutics
AIMT
+$2.62M
4
AERI
Aerie Pharmaceuticals
AERI
+$2.47M
5
PNFP icon
Pinnacle Financial Partners Inc
PNFP
+$2.46M

Top Sells

Rank Stock Value
1
MNRO icon
Monro
MNRO
+$2.43M
2
SNDR icon
Schneider National
SNDR
+$1.89M
3
LHCG
LHC Group LLC
LHCG
+$1.47M
4
MXWL
Maxwell Technologies Inc
MXWL
+$1.21M
5
ASXC
Asensus Surgical, Inc.
ASXC
+$1.09M

Sector Composition

Rank Sector Weight
1 Industrials 21.06%
2 Healthcare 18.93%
3 Financials 12.68%
4 Technology 9.76%
5 Consumer Staples 8.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
76
Madrigal Pharmaceuticals
MDGL
$12.7B
$360K 0.29%
+1,287
New +$226K
NUVA
77
DELISTED
NuVasive, Inc.
NUVA
$358K 0.28%
6,878
+1,419
+26% +$74.3K
EME icon
78
Emcor
EME
$33B
$349K 0.28%
4,598
-5
-0.1% -$388
SUPN icon
79
Supernus Pharmaceuticals
SUPN
$2.73B
$348K 0.28%
+5,832
New +$302K
FIX icon
80
Comfort Systems
FIX
$60.9B
$344K 0.27%
7,513
-8,233
-52% -$367K
SRPT icon
81
Sarepta Therapeutics
SRPT
$1.68B
$341K 0.27%
2,585
-241
-9% -$22.7K
FOLD
82
DELISTED
Amicus Therapeutics
FOLD
$336K 0.27%
+21,522
New +$325K
BPMC
83
DELISTED
Blueprint Medicines
BPMC
$307K 0.24%
4,830
+1,034
+27% +$82.3K
PCH
84
DELISTED
PotlatchDeltic
PCH
$298K 0.24%
5,867
-31
-0.5% -$1.57K
EFOR
85
Everforth Inc
EFOR
$884M
$295K 0.23%
3,775
-4,362
-54% -$357K
PFPT
86
DELISTED
Proofpoint, Inc.
PFPT
$280K 0.22%
2,438
-13
-0.5% -$1.58K
RARE icon
87
Ultragenyx Pharmaceutical
RARE
$2.65B
$279K 0.22%
+3,622
New +$234K
APOG icon
88
Apogee Enterprises
APOG
$855M
$275K 0.22%
5,693
-54
-0.9% -$2.32K
CLVS
89
DELISTED
Clovis Oncology, Inc.
CLVS
$269K 0.21%
5,935
+1,707
+40% +$83K
SLAB icon
90
Silicon Laboratories
SLAB
$7.17B
$266K 0.21%
2,681
-18
-0.7% -$1.8K
EGP icon
91
EastGroup Properties
EGP
$11.3B
$259K 0.21%
2,714
-5,102
-65% -$459K
KYNB
92
Kyntra Bio
KYNB
$28.5M
$254K 0.2%
+161
New +$210K
LPX icon
93
Louisiana-Pacific
LPX
$5.19B
$249K 0.2%
9,115
-1
-0% -$29
CRM icon
94
Salesforce
CRM
$142B
$209K 0.17%
+1,539
New +$196K
MXWL
95
DELISTED
Maxwell Technologies Inc
MXWL
$140K 0.11%
26,932
-223,068
-89% -$1.21M
ACIW icon
96
ACI Worldwide
ACIW
$5.88B
– –
-10,180
Closed -$241K
ANAB icon
97
AnaptysBio
ANAB
$1.59B
– –
-1,976
Closed -$205K
BDC icon
98
Belden
BDC
$4.12B
– –
-3,746
Closed -$258K
CVLT icon
99
Commault Systems
CVLT
$6.19B
– –
-5,969
Closed -$341K
DLX icon
100
Deluxe
DLX
$1.22B
– –
-4,762
Closed -$351K
2 3
4
5 6

Similar funds

CIM
Consilium Investment Management Ft. Lauderdale, Florida $21M AUM 29.5% 1-Year Est. Return
ICP
IBIS Capital Partners London, United Kingdom $19.4M AUM 0.49% 1-Year Est. Return
QI
Quilter Investors London, United Kingdom $22.3M AUM 6.63% 1-Year Est. Return
HWM
Highwater Wealth Management Glendale, Colorado $22.6M AUM 3.46% 1-Year Est. Return
AGU
Alpine Group USVI St. Thomas, U.S. Virgin Islands $23.4M AUM
PCP
Prisma Capital Partners New York $17.5M AUM 42.28% 1-Year Est. Return
MAU
MRA Associates USA Phoenix, Arizona $25.4M AUM 0.38% 1-Year Est. Return
FCG
FrontFour Capital Group Greenwich, Connecticut $26.5M AUM 17.69% 1-Year Est. Return

Pacific View Asset Management's Q2 2018 Portfolio in Review

As of Q2 2018, Pacific View Asset Management held 126 positions worth $126M, down 4.8% from $133M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Pacific View Asset Management withdrew a net $10M in Q2 2018, closing 31 positions and reducing 31 holdings. Its most notable exit was Monro, an estimated $2.43M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 21% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Pacific View Asset Management opened a new position in Array Biopharma Inc worth $3.78M.

  • Pacific View Asset Management's largest Q2 2018 buy was Array Biopharma Inc: 225,511 shares worth $3.78M.
  • Pacific View Asset Management added most to Granite Construction in Q2 2018, an estimated $4.51M increase.
  • Pacific View Asset Management's biggest Q2 2018 reduction was LHC Group LLC, cutting an estimated $1.47M.
  • Pacific View Asset Management fully exited Monro in Q2 2018, selling an estimated $2.43M.
  • Pacific View Asset Management's ten largest holdings make up 44% of its $126M portfolio in Q2 2018.
  • Pacific View Asset Management opened 18 new positions and closed 31 in Q2 2018.
  • Pacific View Asset Management's portfolio value fell 4.8% quarter-over-quarter to $126M.

Based on Pacific View Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.